MIMEDX PROVIDES UPDATE ON PREVIOUSLY ANNOUNCED SENIOR EXECUTIVE SEPARATIONS Board and Compensation Committee Determine That Separations Be Treated as For Cause Terminations Based on Information from Audit Committee s Ong

MIMEDX PROVIDES UPDATE ON PREVIOUSLY ANNOUNCED SENIOR EXECUTIVE SEPARATIONS

Board and Compensation Committee Determine That Separations Be Treated as For Cause

Terminations Based on Information from Audit Committee s Ongoing Independent Investigation

Parker H. Petit Resigns as Member of MiMedx Board, Effective Immediately

Marietta, Georgia, September 20, 2018 The Board of Directors (the Board ) of MiMedx Group, Inc. (Nasdaq: MDXG), a leading

developer and marketer of regenerative and therapeutic biologics, today announced that it has determined that the previously announced separations of four senior MiMedx executives Parker H. Petit, William C. Taylor, Michael J. Senken, and

John E. Cranston (collectively, the Separated Employees ) be treated as terminations for cause . The Compensation Committee separately reached this determination as well. These determinations are based on information

identified as part of the Audit Committee s ongoing independent investigation.

Mr. Petit is the Company s former Chairman and Chief

Executive Officer; Mr. Taylor is the Company s former President and Chief Operating Officer and a former member of the Board; Mr. Senken is the Company s former Chief Financial Officer and principal accounting officer; and

Mr. Cranston is the Company s former Vice President, Corporate Controller and Treasurer. Messrs. Petit and Taylor resigned as officers of the Company effective June 30, 2018, and Messrs. Senken and Cranston stepped down from their

positions on June 6, 2018. Mr. Taylor resigned from the Board effective June 30, 2018.

As a result of findings related to the conduct of

the Separated Employees, the Board and the Compensation Committee, as the administrators of the MiMedx Group, Inc. Assumed 2006 Stock Incentive Plan (the 2006 Plan ) and the MiMedx Group, Inc. 2016 Equity and Cash Incentive Plan (together

with the 2006 Plan, the Plans ), have taken all required action to cause all equity and incentive awards outstanding under the Plans held by the Separated Employees to be forfeited. The Board and Compensation Committee action was based on

findings that the Separated Employees engaged in, among other things, conduct detrimental to the business or reputation of the Company.

Board and the Compensation Committee have determined that action shall be taken to recover compensation previously paid to the Separated Employees pursuant to the Plans and the Company s Compensation Recoupment Policy, based upon the final

results of the Company s restatement of its previously issued consolidated financial statements and financial information.

Additionally, the Board

announced that Mr. Petit has resigned as a member of the MiMedx Board, effective immediately.

The Board is taking the necessary steps to

prepare MiMedx for its next chapter and a stronger future, said Charles R. Evans, Chairman of the Board. The Board is committed to taking the decisive actions necessary to develop enhanced systems and controls. Meanwhile, the Board and

management team remain focused on executing the Company s strategy to deliver operational and clinical successes to improve the lives of patients around the world and drive long-term business success and value creation.

The Audit Committee is working with its advisors to complete the investigation expeditiously and has made significant progress. The investigation is ongoing,

and there may be other actions taken based, at least in part, on information from the investigation. The Company is also working to prepare its financial statements for audit and regain compliance with its Securities and Exchange Commission

reporting obligations as soon as practicable.

MiMedx is a leading biopharmaceutical company developing and marketing regenerative and therapeutic biologics utilizing human placental tissue allografts with patent-protected processes for multiple

sectors of healthcare. Innovations in Regenerative Medicine is the framework behind the Company s mission to provide physicians products and tissues to help the body heal itself. The Company processes the human placental tissue

utilizing its proprietary PURION Process methodology, among other processes, to allografts by employing aseptic processing techniques in addition to terminal sterilization. MiMedx has

supplied over 1.3 million allografts to date for application in the Wound Care, Burn, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic and Dental sectors of healthcare. For additional information, please visit www.mimedx.com.

Safe Harbor Statement

This press release includes

forward-looking statements including statements regarding the Audit Committee s independent investigation and any actions that may arise in connection therewith. Forward-looking statements may be identified by words such as believe,

expect, may, plan, potential, will, would and similar expressions and are based on current beliefs and expectations. Forward-looking statements are subject to risks and

uncertainties, and the Company cautions investors against placing undue reliance on such statements.

Actual results may differ materially from those set

forth in the forward-looking statements as a result of various factors, including, without limitation, uncertainties relating to the outcome of the Audit Committee s investigation. For more detailed information on the risks and uncertainties

that may apply to the Company s business and the ownership of Company common stock, please review the Risk Factors section of the Company s most recent annual report filed with the Securities and Exchange Commission. Any forward-looking

statements speak only as of the date of this press release, and except as required by law, the Company assumes no obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.

Vice President, Investor Relations